MRX-2843 is a first-in-class MERTK-selective inhibitor that is currently being tested alone and in combination with other agents in multiple phase I solid tumor and leukemia clinical trials, including a trial in adolescents and young adults [8]. This evidence concerns the gene MERTK and leukemia.